INTRODUCTION

Endoscopic ultrasonography (EUS) is used to evaluate pathology inside and outside the gastrointestinal tract. Because the endoscope used for EUS is larger and the examination time is longer than that with conventional upper endoscopy, EUS requires sedation. A safe sedation method that minimizes body movements and respiratory and circulatory depression is desirable. To determine the appropriate dosage of sedatives during EUS, objective evaluation criteria must be established. Bispectral index (BIS) monitors process and display electroencephalographic data are used to assess the effects of general anesthesia during surgery. However, the utility of BIS monitoring for sedation management during short procedures, such as EUS, remains unclear. In this study, the value of BIS monitoring during EUS was retrospectively evaluated by assessing the effects of anesthesia in patients with or without BIS monitoring.
METHODS

Study design
This was a single-center, retrospective, comparative study. The primary endpoint was the safety and efficacy of BIS monitoring during EUS examination (Fig. 1). All methods were performed in accordance with the relevant guidelines and regulations.

Patients
This study enrolled 725 consecutive patients (375 male and 350 female patients; median age, 64.9 years) who underwent EUS examination of extra- and intra-gastrointestinal tract pathology between January 2013 and September 2013. A BIS monitor was not used for approximately the first month of the study period, after which the use of the BIS monitor was assigned to patients on a random basis. BIS monitoring was used in 364 patients and not used in 361 patients (BIS group: between January 31 and September 16, 2013; non-BIS group: between January 4 and September 16, 2013). Patients were excluded if they met any of the following criteria: age <20 years, American Society of Anesthesiologists physical status score >5, allergy to midazolam or propofol, cranial nerve diseases, pregnancy, hypoxia with <90% arterial oxygen saturation on pulse oximetry ($SpO_2$), systolic blood pressure (SBP) <90 mmHg, or heart rate (HR) <50 beats per minute (bpm).

Maintaining anesthesia with propofol during EUS
Three physicians were involved in each EUS examination, each assigned a different role: one performed the EUS, one operated the ultrasound equipment, and one monitored the BIS signal and administered propofol. The physicians who administered propofol during EUS were first instructed by anesthesiologists. The EUS procedures were performed by experienced endosonographers, who had each performed more than 1,000 EUS procedures using an echoendoscope (GF-UCT260; Olympus Medical Systems, Tokyo, Japan). Patients received 2 L/min of oxygen during the procedure. Midazolam (0.04–0.05 mg/kg) and propofol (2.0–2.5 mg/kg) were administered to initiate sedation. Additional doses of propofol were administered in 20 mg increments until adequate induction of anesthesia was achieved. After initiating anesthesia, the endosonographers waited for a few minutes to confirm its effect, at which time EUS was started. To maintain sedation, propofol was intermittently administered at a dose of 20 mg based on body movements during EUS in the non-BIS group and on body movements and BIS values in the BIS group. The BIS values were maintained in the range of 60–80. Patients who exhibited a rapid increase in the BIS value or a value >80 were administered an additional 20 mg dose of propofol by a physician other than the endoscopist. A biological information monitor was attached to all patients, and the pulse rate and $SpO_2$ were continuously monitored during the examination. Blood pressure was measured at 5-minute intervals.

Definitions
The following parameters were compared between the two groups: (1) median dose of propofol; (2) respiratory and circulatory depression; (3) occurrence of body movements requiring discontinuation of the examination; (4) awakening score >8 at the time of leaving the endoscopy room; and (5) awakening score >8 at 2 hours after leaving the endoscopy room. Respiratory depression was defined as an $SpO_2$ <90%. Circulatory depression was defined as an SBP of <90 mmHg and/or an HR <50 bpm. The awakening score was calculated according to the anesthesia recovery score, as shown in Table 1. The anesthesia recovery score was calculated using the following parameters: (1) motor activity, (2) respiration, (3) SBP, (4) level of consciousness, and (5) $SpO_2$ saturation. Rest cancellation was possible at a recovery score of >8.
Continuous variables were expressed as means±standard deviation or as medians and ranges, and categorical variables were expressed as proportions. Continuous and categorical variables were analyzed using t-tests and chi-squared tests, respectively. Statistical significance was set at p<0.05. All statistical analyses were performed using SAS ver. 9.4 (SAS Institute, Cary, NC, USA).

Statistical analysis

Ethical statements

The study protocol was approved by the Ethics Committee of the Kindai University Faculty of Medicine (IRB No: 30-038). Informed consent was obtained from all the subjects.

RESULTS

The patient characteristics are shown in Table 2. There were no significant differences between the two groups in the male-to-female ratio or median examination time, but there was a significant difference in the average age. Table 3 presents the main results of the study. Overall (n=725), the BIS group received a

Table 2. Patient characteristics

| Characteristic | Total (n=725) | Age<75 yr (n=544) | Age≥75 yr (n=181) |
|---------------|--------------|------------------|------------------|
| Age (yr)      | BIS           | Non-BIS          | p-value          | BIS           | Non-BIS          | p-value          | BIS           | Non-BIS          | p-value          |
|               | 63.49 (22–88) | 66.25 (29–88)    | 0.003            | 58.94 (22–74)   | 67.28 (29–74)   | 0.002            | 79.13 (75–88)   | 77.94 (75–88)   | 0.018            |
| Sex (male:female) | 193:171      | 182:179          | 0.504            | 156:126        | 126:136         | 0.103            | 37:45         | 56:43         | 0.137            |
| Examination time (min) | 25.41 (8–58) | 26.70 (12–58)    | 0.112            | 25.44 (9–49)   | 27.33 (12–58)   | 0.047            | 25.32 (8–49)   | 25.03 (12–55)   | 0.844            |

Values are presented as median (range). BIS, bispectral index monitor.

Table 3. Principal results of this study

| Variable | Total (n=725) | Age<75 yr (n=544) | Age≥75 yr (n=181) |
|----------|--------------|------------------|------------------|
|          | BIS | Non-BIS | p-value | BIS | Non-BIS | p-value | BIS | Non-BIS | p-value |
| Median dose of propofol (mg) | 159.2 | 167.5 | 0.015 | 163.2 | 172.3 | 0.027 | 145.2 | 154.6 | 0.117 |
| Respiratory and circulatory depression (%) |  |  |  |  |  |  |  |  |  |
| SpO₂ drop | 13.7 | 20.2 | 0.023 | 9.9 | 18.3 | 0.006 | 26.8 | 25.3 | 0.866 |
| SBP drop | 13.6 | 14.4 | 0.667 | 11.3 | 17.6 | 0.049 | 7.3 | 16.2 | 0.108 |
| HR drop | 3.7 | 5.0 | 0.365 | 2.8 | 5.0 | 0.266 | 1.2 | 9.1 | 0.023 |
| Occurrence of body movements (%) | 38.1 | 41.1 | 0.364 | 46.8 | 43.5 | 0.036 | 8.5 | 39.4 | <0.001 |
| Awakening score >8 points (%)a |  |  |  |  |  |  |  |  |  |
| When leaving the room | 22.5 | 23.3 | 0.860 | 24.5 | 24.0 | 0.920 | 21.2 | 15.9 | 0.445 |
| Two hours later | 100 | 100 | 1.000 | 100 | 100 | 1.000 | 100 | 100 | 1.000 |

BIS, bispectral index monitor; SpO₂, arterial oxygen saturation of pulse oximetry; SBP, systolic blood pressure; HR, heart rate.

aAwakening score of more than eight points was calculated at the time of leaving the endoscopic room and two hours after leaving the endoscopic room.
significantly lower median dose of propofol than the non-BIS group (159.2 mg vs. 167.5 mg; \( p = 0.015 \)). The SpO\(_2\) drop was significantly lower in the BIS group than in the non-BIS group (13.7\% vs. 20.2\%; \( p = 0.023 \)). For patients aged <75 years (\( n = 544 \)), significant differences were found between the two groups in the reduction in SBP (11.3\% in the BIS group vs. 17.6\% in the non-BIS group; \( p = 0.049 \)), occurrence of body movements (46.8\% vs. 43.5\%; \( p = 0.036 \)), median dose of propofol (163.2\% vs. 172.3\%; \( p = 0.027 \)), and reduction in \( \text{SpO}_2 \) (9.9\% vs. 18.3\%; \( p = 0.006 \)). These significant differences in respiratory and circulatory depression may be due to the age differences between the BIS and non-BIS groups. Patients aged ≥75 years (\( n = 181 \)) in the BIS group were older than those in the non-BIS group (Table 2). There was no significant difference in the propofol doses. Nevertheless, the decrease in HR was significantly lower in the BIS group than in the non-BIS group (1.2\% vs. 9.1\%; \( p = 0.023 \)). Moreover, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5\% vs. 39.4\%; \( p < 0.001 \)). There were no significant differences between the two groups in the awakening score at the time of leaving the endoscopy room or 2 hours thereafter in both the overall and subgroup analyses.

**DISCUSSION**

The BIS monitor was the first electroencephalographic monitor to be approved for clinical use. It monitors brain waves using an electrode attached to the forehead, and the BIS value is calculated by analyzing the electroencephalogram. The BIS value is an estimate of the depth of anesthesia based on various brain wave components (relative \( \beta \) ratio, SynchFastSlow, QUAlZI, and burst suppression ratio).\(^8\) However, the reference database of brain waves was established using patients anesthetized using isoflurane, thiopental, propofol, or midazolam, combined with nitrous oxide or narcotics.\(^9\) Therefore, it is important to confirm the accuracy of BIS values in the presence of other anesthetic agents because BIS value association with the depth of sedation depends on the type of anesthesia used.\(^8\)

The BIS value is calculated from signals acquired over the previous 60 seconds. Therefore, there is a delay between the value shown on the monitor and the actual value at that moment; hence, it is difficult to base an assessment of the depth of sedation exclusively on the BIS score. Nevertheless, the use of a BIS monitor can help to achieve the optimal depth of sedation by evaluating changes in the BIS value in individual cases. Use of the BIS monitor has been shown to reduce the dose/overdose of anesthetic agents and prevent side effects during surgical anesthesia.\(^13-16\) Lower digestive tract endoscopy, and endoscopic retrograde cholangiopancreatography.\(^7-20\)

In this study, there was a significant reduction in respiratory depression in the non-BIS group, which may be related to the fact that the BIS group was younger than the non-BIS group. It is worth noting that BIS monitoring significantly reduced the amount of propofol used during the examination, even for younger individuals, and reducing the risk of overdose. There was no significant difference in the incidence of bradycardia or body movements, although BIS monitoring was associated with a decrease in these parameters. However, in patients 75 years of age or older, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5\% vs. 39.4\%; \( p < 0.001 \)). Moreover, the decrease in HR was significantly lower in the BIS group than in the non-BIS group (1.2\% vs. 9.1\%; \( p = 0.023 \)), although the patients in the BIS group were older. These results suggest that the BIS monitor can be used as an indicator of the depth of sedation, and thus help guide sedative dosage during endoscopic examination. Propofol is effective over a narrow range of concentrations in the blood and is difficult to maintain at an appropriate level. Thus, BIS monitoring may be particularly useful during EUS examination under propofol sedation. However, the degree of stimulus during EUS depends on the skill of the examiner, and it must be recognized that sedation using the BIS monitor requires a certain level of proficiency.

This study had several limitations. First, this was a retrospective study. There was no record of changes in BIS values during EUS; therefore, we could not determine how many patients exhibited rapid increases in BIS values or had values >80. It was not possible to control the physique, and/or situation during EUS in detail, although there may be various sources of bias in assessing these background factors. In addition, the degree of stimulus and pain experienced by patients differ according to the type of EUS examination. Finally, the difference in age between the BIS and non-BIS groups is a significant limitation. The present results and cost-effectiveness of BIS monitoring need to be confirmed under controlled conditions in future studies.

In conclusion, BIS monitoring is useful for maintaining a constant depth of anesthesia while reducing the dose of propofol. Especially for patients 75 years of age or older, the use of the BIS monitor might limit body movements and the reduction in...
HR that can occur during EUS examinations. The BIS monitor calculates the depth of anesthesia over a period of 60 seconds; therefore, sudden changes are not recorded in real time. The optimal depth of sedation can be determined by analyzing changes in the BIS value. However, respiratory and circulatory depression was observed even when the BIS monitor was used, and these effects should be addressed in future studies.

Conflicts of Interest
The authors have no potential conflicts of interest.

Funding
This work was supported by a grant-in-aid from the Japan Research Foundation for Clinical Pharmacology.

Author Contributions
Conceptualization: KK, TM; Data curation: TYo, RI, TYa, AN, SO, KM, KY; Formal analysis: YC; Funding acquisition: KK; Methodology: KK; Visualization: KK, TM; Writing–original draft: AO; Writing-review & editing: all authors.

ORCID
Ayana Okamoto https://orcid.org/0000-0002-8173-2910
Ken Kamata https://orcid.org/0000-0003-1568-0769
Takeshi Miyata https://orcid.org/0000-0003-4702-2197
Tomoe Yoshikawa https://orcid.org/0000-0001-5275-2667
Rei Ishikawa https://orcid.org/0000-0001-8719-2866
Tomohiro Yamazaki https://orcid.org/0000-0001-8378-1268
Atsushi Nakai https://orcid.org/0000-0002-0569-3948
Shunsuke Omoto https://orcid.org/0000-0001-7291-3608
Kosuke Minaga https://orcid.org/0000-0001-5407-7925
Kentaro Yamao https://orcid.org/0000-0001-2497-7740
Mamoru Takenaka https://orcid.org/0000-0001-7308-4311
Yasutaka Chiba https://orcid.org/0000-0002-7261-2351
Toshiharu Sakurai https://orcid.org/0000-0002-7798-6862
Naoshi Nishida https://orcid.org/0000-0001-6581-7896
Masayuki Kitano https://orcid.org/0000-0001-6885-9223
Masatoshi Kudo https://orcid.org/0000-0002-4102-3474

REFERENCES
1. Kamata K, Takenaka M, Kitano M, et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions. Dig Endosc 2018;30:98–106.
2. Kamata K, Takenaka M, Kitano M, et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of sub-mucosal tumors of the upper gastrointestinal tract. J Gastroenterol Hepatol 2017;32:1686–1692.
3. Cherney DG, Byrne MF. Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. World J Gastroenterol 2014;20:5171–5176.
4. Amornytin S, Leelakusolvong S, Chalayonnawin W, et al. Age-dependent safety analysis of propofol-based deep sedation for ERCP and EUS procedures at an endoscopy training center in a developing country. Clin Exp Gastroenterol 2012;5:123–128.
5. Lee TH, Lee CK, Park SH, et al. Balanced propofol sedation versus propofol monosedation in therapeutic pancreaticobiliary endoscopic procedures. Dig Dis Sci 2012;57:2113–2121.
6. Pagano N, Arosio M, Romeo F, et al. Balanced propofol sedation in patients undergoing EUS-FNA: a pilot study to assess feasibility and safety. Diagn Ther Endosc 2011;2011:542159.
7. Yusof IF, Raymond G, Sahai AV. Endoscopist administered propofol for upper GI EUS is safe and effective: a prospective study in 500 patients. Gastrointest Endosc 2004;60:356–360.
8. Rampi IJ. A primer for EEG signal processing in anesthesia. Anesthesiology 1998;89:980–1002.
9. Glass PS, Bloom M, Kearse L, et al. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 1997;86:836–847.
10. Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth Analg 1970;49:924–934.
11. Lovett P, Gómez V, Hodge DO, et al. Propofol versus midazolam/fentanyl sedation for colonoscopy in the elderly patient population. J Perianesth Nurs 2017;32:210–214.
12. Schmitz A, Weiss M, Kellenberger C, et al. Sedation for magnetic resonance imaging using propofol with or without ketamine in induction in pediatrics: a prospective randomized double-blinded study. Paediatr Anaesth 2018;28:264–274.
13. Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. N Engl J Med 2008;358:1097–1108.
14. O'Connor MF, Daves SM, Tung A, et al. BIS monitoring to prevent awareness during general anesthesia. Anesthesiology 2001;94:520–522.
15. Gan TJ, Glass PS, Windsor A, et al. Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS Utility Study Group. Anesthesiology 1997;87:808–815.
16. Choi WJ, Kim YH. How do you use bispectral index effectively for preventing re-awareness during general anesthesia? Korean J Anesthesiol 2012;62:1–2.
17. Sandler NA, Hodges J, Sabino M. Assessment of recovery in patients undergoing intravenous conscious sedation using bispectral analysis. J Oral Maxillofac Surg 2001;59:603–611.
18. Jang SY, Park HG, Jung MK, et al. Bispectral index monitoring as an adjunct to nurse-administered combined sedation during endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2012;18:6284–6289.
19. von Delius S, Salletmaier H, Meining A, et al. Bispectral index monitoring of midazolam and propofol sedation during endoscopic retrograde cholangiopancreatography: a randomized clinical trial (the EndoBIS study). Endoscopy 2012;44:258–264.
20. Paspatis GA, Chainaki I, Manolaraki MM, et al. Efficacy of bispectral index monitoring as an adjunct to propofol deep sedation for ERCP: a randomized controlled trial. Endoscopy 2009;41:1046–1051.